Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients.

BACKGROUND Positron emission tomography (PET) imaging of brain amyloid (Aβ) and neurofibrillary tangle (NFT) load is a candidate biomarker of Alzheimer's disease (AD). OBJECTIVES To compare brain Aβ and NFT load and glucose metabolism in advanced elderly (70 years and older) patients with AD and healthy controls (HCs) by PET with [18F]FDDNP and [18F]FDG. METHODS Seven AD patients (mean ± SD age 79.3 ± 3.6 y, Mini-Mental State Examination (MMSE) score 22.1 ± 2.5) and eight HCs (mean age ± SD, 75.7 ± 3.9 y; MMSE score 29.0 ± 1.2) underwent PET with [18F]FDDNP and [18F]FDG. RESULTS Global [18F]FDDNP uptake was significantly higher (p < 0.05) in AD patients (1.15 ± 0.04) than in HCs (1.10 ± 0.06), while global brain metabolism was lower in AD patients than in HCs (AD patients 0.96 ± 0.09; HCs 1.13 ± 0.11; p < 0.05). In HCs, brain glucose metabolism was correlated with age for both the global [18F]FDG SUVr and in the parietal and posterior cingulate regions, while no correlation was found between age and [18F]FDDNP uptake. In AD patients, global [18F]FDDNP uptake and uptake in the frontal and anterior cingulate regions of interest were correlated with MMSE score, while no correlation was observed with brain glucose metabolism. CONCLUSION Imaging Aβ load and NFT with [18F]FDDNP can distinguish AD patients from HCs in an advanced elderly population. It seems to be less sensitive than [18F]FDG to the brain changes observed with normal aging, but more sensitive to cognitive decline in advanced elderly AD patients.

[1]  Wei Zhang,et al.  A highly selective and specific PET tracer for imaging of tau pathologies. , 2012, Journal of Alzheimer's disease : JAD.

[2]  James Robert Brašić,et al.  In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.

[3]  Magnus Dahlbom,et al.  Comparative evaluation of Logan and relative-equilibrium graphical methods for parametric imaging of dynamic [18F]FDDNP PET determinations , 2012, NeuroImage.

[4]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[5]  Keith A. Johnson,et al.  Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline , 2012, Neurology.

[6]  L. Thurfjell,et al.  Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease , 2009, Journal of Nuclear Medicine.

[7]  Seong Jin Cho,et al.  Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease , 2008, NeuroImage.

[8]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[9]  B. Schmand,et al.  Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment. , 2012, Journal of Alzheimer's disease : JAD.

[10]  Carol Brayne,et al.  Age, neuropathology, and dementia. , 2009, The New England journal of medicine.

[11]  Frederik Barkhof,et al.  Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  W. Jagust,et al.  Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypothesis In Vivo , 2009, Behavioural neurology.

[13]  D. Selkoe,et al.  Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. , 1989, The American journal of pathology.

[14]  V. Libri,et al.  Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer’s disease pathologies , 2009, Journal of neurochemistry.

[15]  A. Joshi,et al.  Amyloid imaging and cognitive decline in nondemented oldest-old: The 90+ Study , 2013, Alzheimer's & Dementia.

[16]  J. Schneider,et al.  Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.

[17]  John Seibyl,et al.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.

[18]  Mark E. Schmidt,et al.  The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[19]  B. Vellas,et al.  Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Bradley T. Hyman,et al.  Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease , 1992, Neurology.

[21]  H. Buschke,et al.  Screening for dementia by memory testing , 1988, Neurology.

[22]  G. Small,et al.  Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. , 2012, Archives of neurology.

[23]  G. Small,et al.  Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease , 2001, The Journal of Neuroscience.

[24]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[25]  G. Small,et al.  The merits of FDDNP-PET imaging in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[26]  J. O'Brien,et al.  PET imaging of brain amyloid in dementia: a review , 2011, International journal of geriatric psychiatry.

[27]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[28]  Pierrick Bourgeat,et al.  Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. , 2011, Brain : a journal of neurology.

[29]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[30]  J. Price,et al.  The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.

[31]  Karl Herholz,et al.  Clinical amyloid imaging in Alzheimer's disease , 2011, The Lancet Neurology.

[32]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[33]  G. Small,et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[34]  Keith A. Johnson,et al.  Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals , 2013, Neurobiology of Aging.

[35]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[36]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[37]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[38]  Kiralee M. Hayashi,et al.  Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease , 2010, Neurobiology of Aging.

[39]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[40]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[41]  G. Chételat,et al.  Region-Specific Hierarchy between Atrophy, Hypometabolism, and β-Amyloid (Aβ) Load in Alzheimer's Disease Dementia , 2012, The Journal of Neuroscience.

[42]  Bradley T. Hyman,et al.  Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.

[43]  B. Miller,et al.  Cognition, glucose metabolism and amyloid burden in Alzheimer's disease , 2012, Neurobiology of Aging.

[44]  Lars Farde,et al.  Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand , 2010, Journal of neurochemistry.

[45]  C R Jack,et al.  Spotlight on the January 24 Issue , 2012, Neurology.

[46]  Paul M. Thompson,et al.  Prediction of cognitive decline based on hemispheric cortical surface maps of FDDNP PET , 2012, NeuroImage.

[47]  P. Thompson,et al.  PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.

[48]  Nelleke Tolboom,et al.  Evaluation of Tracer Kinetic Models for Analysis of [18F]FDDNP Studies , 2009, Molecular Imaging and Biology.

[49]  Sung-Cheng Huang,et al.  2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.